Mumbai based drug maker Glenmark Pharmaceuticals revealed that it will starting the phase II clinical trials to test the effectiveness of its experimental drug for treating Crohn's disease and other inflammatory conditions in humans.
The trials are being conducted in collaboration with Sanofi to test whether the drug, GBR 500, is effective in treating inflammatory conditions such as Crohn's disease, multiple sclerosis and ulcerative colitis.
The trials are being conducted at multiple clinical sites in North America and Europe by its subsidiary company Glenmark Pharmaceuticals SA.
Glenmark Pharmaceuticals Chief Scientific Officer Michael Buschle revealed that the phase II trials will be expanding the sample base to 100-300 people. "Despite treatment advances in recent years, UC remains a debilitating condition for many individuals, and represents an area of substantial unmet medical need", he said.